Immunotherapy for Cancer in Kidney Transplant Patients: A Difficult Balance Between Risks and Benefits
Cancer is a major cause of morbidity and mortality in kidney transplant patients. Unfortunately, the use of new anti-cancer therapies such as immune checkpoint inhibitors (ICPIs) in this population has been associated with rejection rates up to 40%, in retrospective studies. The main challenge is to...
Hlavní autoři: | , , , , , |
---|---|
Médium: | Článek |
Jazyk: | English |
Vydáno: |
Frontiers Media S.A.
2024-11-01
|
Edice: | Transplant International |
Témata: | |
On-line přístup: | https://www.frontierspartnerships.org/articles/10.3389/ti.2024.13204/full |